Publications by authors named "V Boerlin"

Claim this Profile
A
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
S Ikeda, Y Takano, O Cynshi, R Tanaka, A D Christ, V Boerlin

Diabetes Obes Metab· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
Joost van der Hoek, Aart-Jan van der Lelij, Richard A Feelders, Wouter W de Herder, Piet Uitterlinden, Viktor Boerlin

Clin Endocrinol (Oxf)· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights on SOM230, a universal somatostatin receptor ligand.
V Boerlin, J van der Hoek, Ch Beglinger, K W Poon, S Hartmann

J Endocrinol Invest· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
Joost van der Hoek, Wouter W de Herder, Richard A Feelders, Aart-Jan van der Lely, Piet Uitterlinden, Viktor Boerlin

J Clin Endocrinol Metab· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
A Colao, D Ferone, P Marzullo, P Cappabianca, S Cirillo, V Boerlin

J Clin Endocrinol Metab· June 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis